Inozyme Pharma To Present Recently Announced Data From Phase 1/2 Trials Of INZ-701 In Adults With ENPP1 Deficiency And ABCC6 Deficiency (PXE) At Upcom...
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) --
Source: menafn.com
📰 Label Study News
Label Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Label Study. Real-time updates on events, politics, business and more.
Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT
First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...
United States San Diego Sikander Ailawadhi Francesco Passamonti Lisocabtagene Maraleucel Guillaume Cartron
Source: marketscreener.com
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA under Accelerated Approval Program
PLYMOUTH MEETING - INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious...
United States Jacqueline Shea Kim Mcclellan Jennie Willson Triological Society Recurrent Respiratory Papillomatosis Foundation
Source: marketscreener.com
U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1 - Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical... -Today at 08:04 am- MarketScreener
United States Markj Foley Peter Mcallister Association Of Academic Physiatrists Annual Meeting Peptide Exchange Technology Revance Therapeutics Inc
Source: marketscreener.com
Revance Therapeutics Says FDA Approves DAXXIFY For Injection To Treat Cervical Dystonia In Adults
Revance Therapeutics, Inc. (RVNC) announced Monday that the U.S. Food and Drug Administration (FDA) has approved the first therapeutic indication for DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults.
Revance Therapeutics Inc Drug Administration Peptide Exchange Technology More Such Health News Revance Therapeutics Label Study
Source: rttnews.com
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
– Announced positive 12-month topline results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy – – Advancing Phase 2 trial of EDG-5506 in Becker muscular... -Today at 08:03 am- MarketScreener
Source: marketscreener.com
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the...
Source: prnewswire.com
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and
Source: medindia.net
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2023 Earnings Call Transcript
Operator: Greetings. Welcome to VistaGen Therapeutics Third Quarter Fiscal Year 2023 Results Conference Call. At this time all participants are in a listen-only mode.
Source: insidermonkey.com
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
Pherin acquisition completed; all future royalty payment obligations related to PH94B and PH10 eliminated, three new drug candidates added to Vistagen’s pipelinePH94B Phase 3 program for social anxiety disorder advancing towards important next stepsPH10 Phase 1 study initiated to facilitate plans for Phase 2B develo...
Source: pharmiweb.com